argenx enrols new cohort in Phase II multifocal motor neuropathy study – Pharmaceutical Technology
Immune globulin treatments are the only available MMN therapies – but ARGX-117 could change that. Source: Shutterstock / Kateryna Kon. Netherlands-based immunology company Argenx has